PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6 high uterine leiomyosarcoma to PD-1 blockade.
Wout De WispelaereDaniela AnnibaliSandra TuyaertsJulie MessiaenAsier AntoranzGautam ShankarNikolina DubrojaAlejandro Herreros-PomaresRegina E M Baiden-AmissahMarie-Pauline OrbanMarcello DelfiniEmanuele BerardiThomas Van BrusselRogier SchepersGino PhilipsBram BoeckxMaria Francesca BaiettiLuigi CongedoKiave Yune HoWangYinEmilie BayonAnne-Sophie Van RompuyEleonora LeucciSebastien P TabruynFrancesca BosisioMassimiliano MazzoneDiether LambrechtsFrédéric AmantPublished in: Clinical and translational medicine (2024)
Our findings indicate that aberrant PI3K/mTOR pathway activation contributes to immune escape in uLMS and provides a rationale for combining PI3K/mTOR inhibition with ICB for the treatment of this patient population.